Nurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual Meeting
07 déc. 2022 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in
10 nov. 2022 09h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies
10 nov. 2022 09h00 HE
|
Nurix Therapeutics, Inc.
Biomarker results are a positive demonstration of target engagement for this first-in-class CBL-B inhibitor Biomarker levels achieved with NX-1607 treatment correspond to levels associated with...
Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
03 nov. 2022 09h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
02 nov. 2022 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with...
Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit
26 oct. 2022 07h00 HE
|
Nurix Therapeutics, Inc.
Complete response observed and ongoing in a patient with multiply relapsed/refractory diffuse large B cell lymphoma (DLBCL) Dual BTK degradation and immunomodulatory activity achieved by day 8 and...
Nurix Therapeutics Announces Presentations at the 5th Annual Targeted Protein Degradation (TPD) Summit
19 oct. 2022 09h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced...
Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update
06 oct. 2022 16h01 HE
|
Nurix Therapeutics, Inc.
Completed two registered direct offerings in July raising gross proceeds of $95 million Maintained strong financial position with $413.6 million in cash and marketable securities as of August 31,...
Nurix Therapeutics Announces Six Poster Presentations at the Upcoming Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
05 oct. 2022 08h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced six...
Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors
14 sept. 2022 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced...